CLAIMS

1. A composition comprising at least one anti-inflammatory agent and at least one sulfated polysaccharide, in which the anti-inflammatory agent is selected from the group consisting of steroid drugs and non-steroid anti-inflammatory drugs (NSAIDs) and combinations thereof, in which the anti-inflammatory agent(s) and the sulfated polysaccharide(s) are present in a mutual weight ratio such that there is a synergistic interaction between the anti-inflammatory agent(s) and the sulfated polysaccharide(s), and in which the weight ratio of the one or more anti-inflammatory agents to the one or more sulfated polysaccharides is in the range of 1:0.01 to 1:10.

2. A composition according to Claim 1, in which the anti-inflammatory steroid drug is selected from the group consisting of dexamethasone, prednisolone, mometasone furoate, halomethasone, betamethasone, betamethasone valerate or succinate, fluorocinolone, triamcinolone, clobetasole, diflorazone, Loteprednol etabonate and hydrocortisone and mixtures thereof.

3. A composition according to Claim 1, in which the non-steroidal anti-inflammatory agent is selected from the group consisting of acetaminophen, ibuprofen, diclofenac, aspirin, indomethacin, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, ketoprofen, piroxicam, tramadol, celecoxib and flurbiprofen, or a salt thereof and mixtures thereof.

4. A composition according to Claim 1, in which the sulfated polysaccharide is selected from the group consisting of algal sulfated polysaccharides, sulfated polysaccharides of herbal origin, bacterial sulfated polysaccharides and combinations thereof.

5. A composition according to Claim 1, in which the sulfated polysaccharide is of marine origin selected from the group consisting of unicellular and multicellular algae.

6. A composition according to Claim 1, in which the sulfated polysaccharides are of algae or plant cellular or extracellular origin.

7. A composition according to Claim 1, in which the sulfated polysaccharides are linear or branched polysaccharides.

8. A composition according to Claim 1, further comprising one or more excipients selected from the group consisting of fillers, solvents, stabilizers, suspending agents, emulsifiers, release mediators, viscosity agents, anti-microbial agents and preservatives, and combinations thereof.

9. A composition according to Claim 1, in which the composition is formulated as a dosage form selected from the group consisting of a liquid, a suspension, an emulsion, a foam, a spray, a liposome, a semi-solid, a cream, an ointment, a patch, a particulate formulation, a granulate, a micro-particulate formulation, a nano-particulate formulation, a solid dosage form, a tablet, a capsule, an orally-disintegrable capsule, a mouth wash and an adhesive buccal tablet.

10. A composition according to Claim 1, in which the release profile of the composition is selected from the group consisting of immediate, delayed, controlled, sustained and prolonged.

11. Use of a composition according to any preceding claim in the preparation of a medicament for treating inflammation.

12. Use according to Claim 11, in which the inflammation is associated with one or more conditions selected from the group consisting of infection due to bacteria, viruses or fungi, allergens, cancer, and physical, chemical, autoimmune disease or thermal trauma.

13. Use according to Claim 11, in which the inflammation is associated with a disease selected from one or more of a disease, disorder or condition selected from the group consisting of eye diseases, dry eyes, kerato conjunctivitis, wounds, ulcerative and diabetic wounds, oral mucositis, chemotherapy, radiation-induced inflammation, inflammatory bowel diseases, liver diseases, skin infections, skin allergies, psoriasis, mucosal inflammation and gastro-intestinal infections and inflammations, ear diseases or infections, throat or gum inflammations, vaginal inflammation and anal inflammation.